UCB Executive and Leadership Team

Charlotte Daehn, the Chief Financial Officer at UCB, directs the company's global financial strategy and operations. Daehn oversees all aspects of financial planning, reporting, and capital allocation, ensuring robust fiscal health and supporting UCB's long-term growth objectives in immunology and neurology. This leadership role involves managing investment portfolios, optimizing resource deployment, and maintaining strong relationships with financial institutions and investors worldwide. Daehn's financial acumen is critical for navigating complex market dynamics and driving sustainable value creation for stakeholders. By meticulously managing financial resources, Charlotte Daehn ensures the company's capacity to fund vital research and development initiatives, directly impacting the delivery of innovative therapies to patients with severe diseases.

Derek Xie, the Head Chief Financial Officer, Broad Market, Retail Distribution (China) at UCB, spearheads financial operations and strategic planning specifically for UCB's broad market and retail distribution channels within China. Xie manages financial performance, budgeting, and investment strategies tailored to the unique demands of the Chinese market, ensuring fiscal discipline and growth. This critical role involves optimizing financial structures to support UCB's expansion in immunology and neurology therapeutics across China's diverse retail landscape. By providing targeted financial leadership, Derek Xie enables the effective distribution and accessibility of UCB's innovative treatments to a wider patient population. Xie's financial oversight is instrumental in navigating regulatory environments and market complexities, driving operational efficiency and profitability for UCB in this key region.

Steve Otten, the Market President at UCB, directs UCB's strategic operations and commercial activities within a designated market, driving business growth and ensuring alignment with global objectives. Otten oversees the execution of market-specific strategies focused on delivering value to patients living with severe immunological and neurological diseases. This leadership position involves managing cross-functional teams, fostering key partnerships, and optimizing resource allocation to maximize market penetration and patient access to UCB's innovative therapies. By championing UCB's mission, Steve Otten ensures that the company's scientific advancements translate into tangible benefits for patients and healthcare systems. Otten's market leadership is crucial for adapting global strategies to local needs, thereby enhancing UCB's impact and reputation.

Michael Davis, the Senior Vice President, Chief Marketing Officer, Head of Stakeholder Integration at UCB, architects the company's global marketing initiatives and stakeholder engagement strategies. Davis leads the development and execution of comprehensive marketing plans that amplify UCB's mission in immunology and neurology, ensuring alignment with patient needs and market opportunities. This executive function involves fostering strong connections with healthcare professionals, patient advocacy groups, and other key stakeholders to drive understanding and adoption of UCB's therapeutic solutions. Overseeing integrated communication efforts, Michael Davis ensures a unified brand message across all platforms. The strategic integration of stakeholder perspectives informs product development and market access, directly supporting UCB's commitment to improving the lives of individuals living with severe diseases.